TreviPay Introduces All-in-One Payments Solution for Accepting Net Terms and Card Payments at Checkout
5.12.2023 15:00:00 EET | Business Wire | Press release
TreviPay, the global B2B payments and invoicing network, today released a series of technology features designed to help merchants build experiential loyalty with enterprise buyers, including TreviPay’s new all-in-one payments solution. By providing payment choice, convenience and customization, merchants across different industries, including retail, hospitality and manufacturing, can leverage TreviPay’s technology to reduce friction and build loyalty at all stages of the purchasing process.
Recent TreviPay research unveiled the importance of payment choice for optimizing first-time and returning buyer experiences with 86% of global business buyers reporting the ability to pay using their preferred payment method is important. With TreviPay’s all-in-one payments, B2B merchants and marketplaces can now serve the entire spectrum of business buyers with TreviPay as their single payments vendor. Through integration, merchants can customize acceptance of card types, allowing business buyers to either pay upfront with card, ACH or mobile wallet, or pay later through net terms (the ability to pay in 30-, 60-, or 90-days) and invoicing to improve cash flow and reduce bad debt.
“As enterprises continue to evaluate their digital transformation efforts, there is still an opportunity to innovate the online B2B payments experience to eliminate checkout friction and increase conversions,” said Dan Zimmerman, Chief Technology Officer of TreviPay. “Through one comprehensive checkout solution, merchants can rely on a single payments vendor to accept multiple payments modalities and consolidate reporting across payment types.”
A notable use case is found in the B2B retail industry where credit cards are often the only payment option offered online. As trade credit or net terms are preferred by 85% of global business buyers, typically for higher spend or more frequent purchases, retailers can now accommodate both options more seamlessly through TreviPay’s all-in-one payments solution. Credit and debit card payments are supported for customers in the U.S., Canada, Mexico, U.K., Europe and Australia, in 16 payout currencies and 25+ locales. TreviPay APIs also provide integrated reporting to systematically deliver detailed reimbursement documentation daily, as well as consolidated reporting for card and net terms payments and deposits — at the marketplace and individual seller levels.
Additional technology capabilities now offered by TreviPay to bolster buyer loyalty include:
- Decentralized Billing: For sellers to create billing groups and sub-tiered accounts (parent/child hierarchy) with separate legal entities, to configure custom payment and billing options, as well as apply individual credit limits.
- Contract Price Verification: For sellers to define customer pricing tiers with specific SKU-level pricing details, for TreviPay to conveniently cross-reference against contracted pricing with limited disruption.
- Customized Customer Support: For sellers to define and rank buyers to customize support with white-glove services, such as offering extended net terms or assigning a dedicated support agent.
- Customer Portal Redesign: To improve navigation, usability and customer experience for buyers, with easy-to-export data capabilities.
To learn more about TreviPay’s solutions for growing B2B experiential loyalty, visit www.trevipay.com.
About TreviPay
At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail and transportation. For more information, visit trevipay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205023858/en/
Contact information
Alissa Clayton
The Fletcher Group
647.390.9085
alissa@fletchergroupllc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
